Results 1 to 10 of about 80 (78)

Oral anticoagulants in the prevention of thromboembolic complications in cardiac patients: analysis of use in the Russian Federation

Качественная клиническая практика, 2020
In last years, special attention has been paid in the Russian Federation (RF) to improving medical care for patients with atrial fibrillation (AF) and the prevention of thromboembolic complications (TEC).
A. A. Gruzdeva, A. A. Khokhlov, M. V. Ilyin   +2 more
doaj   +1 more source

Pharmacoeconomic evaluation of apixaban use for the treatment and prevention of venous thromboembolism in the general population and patients with oncological diseases

Качественная клиническая практика, 2023
Aim. To conduct a pharmacoeconomic analysis of the use of the drug Eliquis® (apixaban), belonging to direct oral anticoagulants (DOACs), for the treatment and prevention of deep vein thrombosis (DVT) and/or pulmonary embolism (PE), including in patients ...
A. S. Kolbin, A. R. Kasimova, S. R. Gilyarevskiy   +2 more
doaj   +1 more source

ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

Рациональная фармакотерапия в кардиологии, 2015
Atrial fibrillation (AF) is a risk factor for thromboembolic complications, requiring administration of vitamin K antagonists (warfarin) or the new oral anticoagulants (apixaban, dabigatran and rivaroxaban).Aim. To assess the influence of apixaban use on
A. V. Rudakova
doaj   +1 more source

COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION

Рациональная фармакотерапия в кардиологии, 2015
Background. For prevention of thromboembolic events in patients with non-valvular atrial fibrillation (NVAF) the following types of antithrombotic therapy are used: anticoagulant therapy with vitamin K antagonists (such as warfarin), antiplatelet therapy
A. V. Rudakova, V. A. Parfenov
doaj   +1 more source

Prognosis and prevention of cardioembolic stroke in patients with atrial fibrillation

Медицинский совет, 2013
The article is a review of literature on the prognosis and prevention of stroke in patients with atrial fibrillation (AF). It is noted that the simple CHA2DS2-VASc calculator is a good predictor of the risk of stroke in AF.
V. А. Parfyonov, S. V. Verbitskaya
doaj   +1 more source

АПИКСАБАН В ЛЕЧЕНИИ ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ

Атеротромбоз, 2015
Сердечно-сосудистые заболевания — наиболее распространенные патологии в России. Они обусловливают более 50% летальных случаев, значительная доля которых ассоциирована с развитием системных тромбоэмболий и инсульта.
О. О. Шахматов, Е. П. Панченко   +1 more
doaj   +1 more source

NEW ORAL ANTICOAGULANTS IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION AND CHRONIC KIDNEY DISEASE

Атеротромбоз, 2015
About 10% of the adult population is diagnosed with chronic kidney disease (CKD), and its presence is associated with a high risk of developing cardiovascular diseases including ventricular fibrillation (VF).
E. P. Panchenko
doaj   +1 more source

NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY

Рациональная фармакотерапия в кардиологии, 2015
Comparative analysis of oral anticoagulants (vitamin K antagonists and new drugs, including dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety.
D. A. Napalkov, A. A. Sokolova
doaj   +1 more source

Comparative pharmacoeconomic analysis of the use of apixaban, rivaroxaban and dabigatran for prevention of stroke and embolism in the vessels of the systemic circulation in patients with non-valvular atrial fibrillation

Качественная клиническая практика, 2023
Aim. To compare the effectiveness of direct oral anticoagulants (DOACs) in patients with non-valvular atrial fibrillation (AF) for preventing stroke and systemic thromboembolism (embolism in the vessels of the systemic circulation, systemic embolism) in ...
A. S. Kolbin, A. R. Kasimova, S. R. Gilyarevskiy   +2 more
doaj   +1 more source

PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION

Рациональная фармакотерапия в кардиологии, 2015
For prevention of thromboembolic events in patients with non-valvular atrial fibrillation (NVAF) the following types of antithrombotic therapy are used: anticoagulant therapy with vitamin K antagonists (warfarin), antiplatelet therapy (acetylsalicylic ...
A. V. Rudakova
doaj   +1 more source